These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
83. Integrating new therapies in the treatment of advanced melanoma. Curti BD; Urba WJ Curr Treat Options Oncol; 2012 Sep; 13(3):327-39. PubMed ID: 22743761 [TBL] [Abstract][Full Text] [Related]
84. The anti-apoptotic BAG3 protein is involved in BRAF inhibitor resistance in melanoma cells. Guerriero L; Palmieri G; De Marco M; Cossu A; Remondelli P; Capunzo M; Turco MC; Rosati A Oncotarget; 2017 Oct; 8(46):80393-80404. PubMed ID: 29113311 [TBL] [Abstract][Full Text] [Related]
85. BRAF Mutations in Melanoma: Biological Aspects, Therapeutic Implications, and Circulating Biomarkers. Castellani G; Buccarelli M; Arasi MB; Rossi S; Pisanu ME; Bellenghi M; Lintas C; Tabolacci C Cancers (Basel); 2023 Aug; 15(16):. PubMed ID: 37627054 [TBL] [Abstract][Full Text] [Related]
86. Ruptured hepatic metastases of cutaneous melanoma during treatment with vemurafenib: an autopsy case report. Nosaka T; Hiramatsu K; Nemoto T; Saito Y; Ozaki Y; Takahashi K; Naito T; Ofuji K; Matsuda H; Ohtani M; Suto H; Imamura Y; Nakamoto Y BMC Clin Pathol; 2015; 15():15. PubMed ID: 26346246 [TBL] [Abstract][Full Text] [Related]
87. Combination of a STAT3 inhibitor with anti-PD-1 immunotherapy is an effective treatment regimen for a vemurafenib-resistant melanoma. Kim TW; Kim Y; Keum H; Jung W; Kang M; Jon S Mol Ther Oncolytics; 2022 Sep; 26():1-14. PubMed ID: 35784401 [TBL] [Abstract][Full Text] [Related]
88. Prolonged Response Induced by Single Agent Vemurafenib in a Garnier L; Ducray F; Verlut C; Mihai MI; Cattin F; Petit A; Curtit E Front Oncol; 2019; 9():177. PubMed ID: 30984614 [TBL] [Abstract][Full Text] [Related]
89. Elucidating molecular mechanisms of acquired resistance to BRAF inhibitors in melanoma using a microfluidic device and deep sequencing. Han J; Jung Y; Jun Y; Park S; Lee S Genomics Inform; 2021 Mar; 19(1):e2. PubMed ID: 33840166 [TBL] [Abstract][Full Text] [Related]
90. Mechanisms of Melanoma Progression and Treatment Resistance: Role of Cancer Stem-like Cells. Al Hmada Y; Brodell RT; Kharouf N; Flanagan TW; Alamodi AA; Hassan SY; Shalaby H; Hassan SL; Haikel Y; Megahed M; Santourlidis S; Hassan M Cancers (Basel); 2024 Jan; 16(2):. PubMed ID: 38275910 [TBL] [Abstract][Full Text] [Related]
92. Inhibition of the Rho/MRTF pathway improves the response of BRAF-resistant melanoma to PD1/PDL1 blockade. Foda BM; Misek SA; Gallo KA; Neubig RR Int J Cancer; 2024 Jun; ():. PubMed ID: 38898604 [TBL] [Abstract][Full Text] [Related]
93. Oncogene-directed small molecule inhibitors for the treatment of cutaneous melanoma. Eliades P; Flaherty KT; Tsao H Melanoma Manag; 2015 May; 2(2):133-147. PubMed ID: 30190843 [TBL] [Abstract][Full Text] [Related]
94. Response to Vemurafenib in Metastatic Triple-Negative Breast Cancer Harbouring a BRAF V600E Mutation: A Case Report and Electronically Captured Patient-Reported Outcome. Pircher M; Winder T; Trojan A Case Rep Oncol; 2021; 14(1):616-621. PubMed ID: 33976643 [TBL] [Abstract][Full Text] [Related]
95. Tumorigenesis driven by the BRAF Gadal S; Boyer JA; Roy SF; Outmezguine NA; Sharma M; Li H; Fan N; Chan E; Romin Y; Barlas A; Chang Q; Pancholi P; Timaul NM; Overholtzer M; Yaeger R; Manova-Todorova K; de Stanchina E; Bosenberg M; Rosen N bioRxiv; 2024 Apr; ():. PubMed ID: 38659913 [No Abstract] [Full Text] [Related]
96. NLRP1 Functions Downstream of the MAPK/ERK Signaling via ATF4 and Contributes to Acquired Targeted Therapy Resistance in Human Metastatic Melanoma. Zhai Z; Vaddi PK; Samson JM; Takegami T; Fujita M Pharmaceuticals (Basel); 2020 Dec; 14(1):. PubMed ID: 33396632 [TBL] [Abstract][Full Text] [Related]
97. A case report of metastatic giant sarcomatoid melanoma with BRAF V600E mutation: a complete response to targeted therapy. Torresetti M; Brancorsini D; Morgese F; Cognigni V; Scalise A; Berardi R; Di Benedetto G Oncotarget; 2020 Aug; 11(34):3256-3262. PubMed ID: 32922664 [TBL] [Abstract][Full Text] [Related]
98. Aggressive Childhood-onset Papillary Craniopharyngioma Managed With Vemurafenib, a BRAF Inhibitor. Chik CL; van Landeghem FKH; Easaw JC; Mehta V J Endocr Soc; 2021 May; 5(5):bvab043. PubMed ID: 33928205 [TBL] [Abstract][Full Text] [Related]
99. Protein Expression in Metastatic Melanoma and the Link to Disease Presentation in a Range of Tumor Phenotypes. Kim Y; Gil J; Pla I; Sanchez A; Betancourt LH; Lee B; Appelqvist R; Ingvar C; Lundgren L; Olsson H; Baldetorp B; Kwon HJ; Oskolás H; Rezeli M; Doma V; Kárpáti S; Szasz AM; Németh IB; Malm J; Marko-Varga G Cancers (Basel); 2020 Mar; 12(3):. PubMed ID: 32213878 [TBL] [Abstract][Full Text] [Related]
100. Deregulated FASN Expression in BRAF Inhibitor-Resistant Melanoma Cells Unveils New Targets for Drug Combinations. Stamatakos S; Beretta GL; Vergani E; Dugo M; Corno C; Corna E; Tinelli S; Frigerio S; Ciusani E; Rodolfo M; Perego P; Gatti L Cancers (Basel); 2021 May; 13(9):. PubMed ID: 34068792 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]